Division of Hematology-Oncology Department of Internal Medicine, James H. Quillen College of Medicine, East Tennessee State University, Dogwood Avenue, Building 119, Johnson City, USA.
Department of Pharmaceutical Sciences, Bill Gatton College of Pharmacy, East Tennessee State University, Johnson City, TN 37614, USA.
BMC Cancer. 2020 May 15;20(1):428. doi: 10.1186/s12885-020-06947-6.
α-tocopherol (AT) and γ-tocotrienol (GT3) are vitamin E isoforms considered to have potential chemopreventive properties. AT has been widely studied in vitro and in clinical trials with mixed results. The latest clinical study (SELECT trial) tested AT in prostate cancer patients, determined that AT provided no benefit, and could promote cancer. Conversely, GT3 has shown antineoplastic properties in several in vitro studies, with no clinical studies published to date. GT3 causes apoptosis via upregulation of the JNK pathway; however, inhibition results in a partial block of cell death. We compared side by side the mechanistic differences in these cells in response to AT and GT3.
The effects of GT3 and AT were studied on androgen sensitive LNCaP and androgen independent PC-3 prostate cancer cells. Their cytotoxic effects were analyzed via MTT and confirmed by metabolic assays measuring ATP. Cellular pathways were studied by immunoblot. Quantitative analysis and the determination of relationships between cell signaling events were analyzed for both agents tested. Non-cancerous prostate RWPE-1 cells were also included as a control.
The RAF/RAS/ERK pathway was significantly activated by GT3 in LNCaP and PC-3 cells but not by AT. This activation is essential for the apoptotic affect by GT3 as demonstrated the complete inhibition of apoptosis by MEK1 inhibitor U0126. Phospho-c-JUN was upregulated by GT3 but not AT. No changes were observed on AKT for either agent, and no release of cytochrome c into the cytoplasm was detected. Caspases 9 and 3 were efficiently activated by GT3 on both cell lines irrespective of androgen sensitivity, but not in cells dosed with AT. Cell viability of non-cancerous RWPE-1 cells was affected neither by GT3 nor AT.
c-JUN is a recognized master regulator of apoptosis as shown previously in prostate cancer. However, the mechanism of action of GT3 in these cells also include a significant activation of ERK which is essential for the apoptotic effect of GT3. The activation of both, ERK and c-JUN, is required for apoptosis and may suggest a relevant step in ensuring circumvention of mechanisms of resistance related to the constitutive activation of MEK1.
α-生育酚(AT)和γ-生育三烯酚(GT3)是被认为具有潜在化学预防特性的维生素 E 异构体。AT 已在体外和临床试验中进行了广泛研究,结果喜忧参半。最近的临床研究(SELECT 试验)测试了 AT 在前列腺癌患者中的作用,结果表明 AT 没有益处,反而可能促进癌症。相反,GT3 在几项体外研究中显示出抗肿瘤特性,但迄今为止尚未发表临床研究。GT3 通过上调 JNK 途径引起细胞凋亡;然而,抑制作用会导致细胞死亡部分受阻。我们并排比较了这些细胞对 AT 和 GT3 反应的机制差异。
研究了 GT3 和 AT 对雄激素敏感的 LNCaP 和雄激素非依赖性 PC-3 前列腺癌细胞的影响。通过 MTT 分析它们的细胞毒性作用,并通过测量 ATP 的代谢测定法进行验证。通过免疫印迹研究细胞途径。对两种测试药物的细胞信号事件之间的关系进行了定量分析和确定。还包括非癌前列腺 RWPE-1 细胞作为对照。
GT3 显著激活了 RAF/RAS/ERK 途径在 LNCaP 和 PC-3 细胞中,但 AT 没有。这种激活对于 GT3 的凋亡作用是必不可少的,因为 MEK1 抑制剂 U0126 的完全抑制了凋亡。磷酸化 c-JUN 被 GT3 上调,但不是 AT。两种药物都没有观察到 AKT 的变化,也没有检测到细胞质中细胞色素 c 的释放。GT3 有效地激活了两种细胞系中的 caspase 9 和 3,无论雄激素敏感性如何,但在 AT 处理的细胞中则没有。非癌 RWPE-1 细胞的细胞活力既不受 GT3 也不受 AT 的影响。
c-JUN 是凋亡的公认主调控因子,如先前在前列腺癌中所示。然而,GT3 在这些细胞中的作用机制还包括 ERK 的显著激活,这对于 GT3 的凋亡作用是必不可少的。ERK 和 c-JUN 的激活对于凋亡都是必需的,这可能表明在确保绕过与 MEK1 组成性激活相关的耐药机制方面的一个相关步骤。